Form 4: Sarepta EVP Disposes Shares for Tax Withholding

Sarepta Therapeutics' EVP and General Counsel, Cristin Rothfuss, disposed of 408 common shares to cover tax obligations related to restricted stock unit vesting.

Summary

• Cristin Rothfuss, EVP and General Counsel of Sarepta Therapeutics, Inc. (SRPT), reported a disposition of common stock.
• The transaction involved 408 shares of common stock.
• The shares were disposed of at a price of $16.2 per share.
• The disposition was made to satisfy tax withholding obligations related to the vesting of restricted stock units granted on March 1, 2024.
• Following this transaction, Ms. Rothfuss beneficially owns 139,348 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, typical for executive compensation and tax planning, with no direct positive or negative implications for the company's operational or financial performance.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, particularly those related to tax withholdings from RSU vesting, are common and generally considered routine administrative events in publicly traded companies. They typically do not reflect a change in management's outlook on the company's performance or future prospects.

Stakeholder Impact

• Minimal direct impact on shareholders as this is a routine administrative transaction for executive compensation and tax purposes.
• No direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Sarepta Therapeutics, SRPT, Form 4, Insider Transaction, Stock Disposition, Tax Withholding, Restricted Stock Units, Executive Compensation